Quoin Pharmaceuticals (QNRX) Expected to Announce Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Quoin Pharmaceuticals to post earnings of ($6.42) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 PM ET.

Quoin Pharmaceuticals Trading Down 2.7%

Shares of NASDAQ QNRX opened at $8.50 on Thursday. The company’s 50-day moving average price is $10.10 and its 200 day moving average price is $11.04. Quoin Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $41.80. The stock has a market cap of $7.14 million, a price-to-earnings ratio of -0.27 and a beta of 1.60.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, December 22nd. Wall Street Zen raised Quoin Pharmaceuticals to a “sell” rating in a research note on Saturday, November 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Quoin Pharmaceuticals presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new stake in shares of Quoin Pharmaceuticals during the fourth quarter worth $3,052,000. Millennium Management LLC purchased a new position in Quoin Pharmaceuticals during the fourth quarter worth about $1,080,000. SummitTX Capital L.P. purchased a new position in Quoin Pharmaceuticals during the fourth quarter worth about $935,000. Boothbay Fund Management LLC acquired a new stake in Quoin Pharmaceuticals in the 4th quarter worth about $863,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Quoin Pharmaceuticals in the 4th quarter valued at about $840,000. 8.63% of the stock is currently owned by institutional investors and hedge funds.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.